Bubs Australia Ltd. (AU:BUB) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bubs Australia Limited has reached a pivotal point in its clinical trial by enrolling the 400th infant, marking a significant step towards securing permanent market access in the U.S. Upon the FDA’s expected approval in October 2025, Bubs aims to finalize its position as the leading goat milk formula brand in the United States. The company has been building a trust-based relationship with American families since first importing its formulas during the 2022 shortage, under the ‘Operation Fly Formula’ program.
For further insights into AU:BUB stock, check out TipRanks’ Stock Analysis page.